Pfizer taps litigator as new GC

Say hello to Pfizer's new general counsel, Amy Schulman (photo), a top litigator who's served as lead attorney on the company's Celebrex and Bextra cases. A partner at DLA Piper, Schulman specializes in defending companies against big product liability lawsuits. She's a top producer for that firm who earned $5.75 million last year. Schulman, 47, replaces Allen Waxman, who left Pfizer in March for personal reasons; she'll report directly to CEO Jeff Kindler, who's also a lawyer. “Her knowledge of the legal, business and regulatory challenges facing the pharmaceutical industry and her experience tackling large, complex cases make her uniquely qualified to lead Pfizer’s legal team," Kindler said in a statement.

- find Pfizer's release
- see the Wall Street Journal story
- check out the WSJ Law Blog's item

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.